Story perspectives

Cancer Breakthrough: CEL-SCI's Multikine Cuts Death Risk 66%

6/19/2025

46 5

Summary

Story summary

CEL-SCI Corporation, located in Virginia, specializes in cancer immunotherapy with its lead drug, Multikine, intended for pre-surgery application.
Multikine demonstrated a 66% reduction in death risk for patients with low PD-L1 expression, surpassing standard treatments.
The company plans to initiate a confirmatory study for FDA approval, aiming at a large patient demographic.
Recent capital raises bolster clinical trials, with analysts forecasting significant stock price growth due to Multikine's market potential.

1 of 1

Story summary

CEL-SCI Corporation, located in Virginia, specializes in cancer immunotherapy with its lead drug, Multikine, intended for pre-surgery application.
Multikine demonstrated a 66% reduction in death risk for patients with low PD-L1 expression, surpassing standard treatments.
The company plans to initiate a confirmatory study for FDA approval, aiming at a large patient demographic.
Recent capital raises bolster clinical trials, with analysts forecasting significant stock price growth due to Multikine's market potential.